Entera Bio Ltd. (ENTX) stock
Close on Nov 12, 2026Market cap $557.52MP/E –Yield –
Entera Bio Ltd. saw revenue fall 100.0% to $0 over the twelve months to Sep 30, 2026. Free cash flow was -$15.84M. At the latest close the market valued the company at $557.52M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $557.52M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.03
- Dividend yield
- –
- Free cash flow yield
- -2.84%
Fundamentals
- Revenue
- $0
- Net income
- -$29.43M
- EPS, diluted
- $0.25
- Free cash flow
- -$15.84M
- Book value per share
- $1.89
- Diluted shares
- 145M
Trading
- Next earnings
- Mar 26, 2027 (estimated, after the close)
- Previous close
- $3.22
- Open
- $3.20
- Day's range
- $3.13 – $3.24
- Volume
- 170,483
- Average volume (20 days)
- 351,046
- Beta (5 years)
- 0.63
- 52-week range
- $0.91 – $4.20
- RSI (14 days)
- 60.1
- Volatility (1 year)
- 126.9%
- Relative volume
- 0.12×
- WACC
- 8.0%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENTX | S&P 500 | Difference | ENTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.5% | -2.7% | +24.2 pts | ||
| 3 months | +15.0% | -1.7% | +16.7 pts | ||
| Year to date | +66.0% | +11.9% | +54.1 pts | ||
| 1 year | +10.7% | +12.0% | −1.3 pts | ||
| 3 years | +360.0% | +78.2% | +281.8 pts | +66.3% | +21.2% |
| 5 years | -15.3% | +73.2% | −88.5 pts | -3.3% | +11.6% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Entera Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Results
About Entera Bio
Biological Products, (No Diagnostic Substances)
Entera Bio Ltd. is a clinical-stage biopharmaceutical company that develops oral tablet formulations of peptides and protein replacement therapies. The company utilizes its proprietary delivery platform to stabilize large peptides in the gastrointestinal tract and support absorption into the bloodstream. Its drug pipeline includes EB613, an oral bone-building tablet candidate for postmenopausal osteoporosis, as well as EB612 for hypoparathyroidism. The company also advances early-stage oral programs for obesity, metabolic disorders, and rare gastrointestinal diseases. Its target consumers are patients living with chronic conditions that typically require frequent injections.
Company profile, executives and historyEntera Bio stock: common questions
What is Entera Bio's stock price?
ENTX closed at $3.22 on Nov 12, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $0.91 and $4.20.
What is Entera Bio's market cap?
Entera Bio was worth $557.52M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does Entera Bio make?
Entera Bio reported revenue of $0 for the twelve months to Sep 30, 2026, down 100.0% from a year earlier.
Does Entera Bio pay a dividend?
No. Entera Bio has not paid a cash dividend over the last twelve months.
When does Entera Bio report earnings next?
Entera Bio is expected to report Q4 FY2026 results on Mar 26, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ENTX stock performed over the past year?
Including dividends, ENTX returned +10.7% over the past year, against +12.0% for the S&P 500.
How many ENTX shares are sold short?
7M shares were sold short at the latest FINRA report, 4.61% of the float, or 15.6 days of average trading volume.
Who are Entera Bio's competitors?
Companies most similar to Entera Bio by business, industry and size include INMB, CNBX, ALT, VIVS, AVTX.
See a number that looks wrong?